Cubist Systematic Strategies LLC Makes New Investment in The Chemours Company (NYSE:CC)

Cubist Systematic Strategies LLC acquired a new position in shares of The Chemours Company (NYSE:CC - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 248,967 shares of the specialty chemicals company's stock, valued at approximately $4,208,000. Cubist Systematic Strategies LLC owned about 0.17% of Chemours at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Barclays PLC lifted its position in shares of Chemours by 28.4% in the third quarter. Barclays PLC now owns 107,549 shares of the specialty chemicals company's stock worth $2,185,000 after purchasing an additional 23,766 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Chemours by 99.7% in the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after purchasing an additional 765 shares in the last quarter. Matrix Trust Co lifted its position in shares of Chemours by 715.7% in the fourth quarter. Matrix Trust Co now owns 9,952 shares of the specialty chemicals company's stock worth $168,000 after purchasing an additional 8,732 shares in the last quarter. Inspire Investing LLC lifted its position in shares of Chemours by 17.4% in the fourth quarter. Inspire Investing LLC now owns 23,799 shares of the specialty chemicals company's stock worth $402,000 after purchasing an additional 3,523 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Chemours by 38.2% in the fourth quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock worth $104,000 after purchasing an additional 1,708 shares in the last quarter. Institutional investors own 76.26% of the company's stock.

Chemours Stock Performance

Shares of NYSE:CC traded down $0.31 on Thursday, hitting $11.12. The company had a trading volume of 1,043,242 shares, compared to its average volume of 2,001,597. The Chemours Company has a 1-year low of $9.33 and a 1-year high of $29.18. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of 19.47 and a beta of 1.76. The stock has a 50 day moving average price of $12.41 and a 200 day moving average price of $16.40. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter in the prior year, the firm earned $0.32 earnings per share. Chemours's revenue for the quarter was up .4% on a year-over-year basis. Analysts expect that The Chemours Company will post 2.03 EPS for the current year.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were paid a $0.25 dividend. The ex-dividend date of this dividend was Friday, February 28th. This represents a $1.00 annualized dividend and a dividend yield of 9.00%. Chemours's dividend payout ratio (DPR) is presently 175.00%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. UBS Group cut their price objective on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Royal Bank of Canada cut their price objective on shares of Chemours from $17.00 to $14.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. StockNews.com lowered shares of Chemours from a "hold" rating to a "sell" rating in a research report on Thursday, May 8th. The Goldman Sachs Group dropped their price target on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Barclays dropped their price target on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $17.56.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.